External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.
about
Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Prospective validation of neonatal vancomycin dosing regimens is urgently needed.Clinical pharmacology in neonates: small size, huge variabilityPredictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermiaPopulation pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.Association between vancomycin trough concentration and area under the concentration-time curve in neonatesCystatin C as a potential biomarker for dosing of renally excreted drugs.Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question.Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtrationTowards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in NeonatesA Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young InfantsPharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Tailored tools to improve pharmacotherapy in infants.Dosage individualization in children: integration of pharmacometrics in clinical practice.Neonatal medicines research: challenges and opportunities.How to use vancomycin optimally in neonates: remaining questions.Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Therapeutic drug monitoring in neonates.Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.The amikacin research program: a stepwise approach to validate dosing regimens in neonates.Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development.Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.
P2860
Q33797950-80A897F5-0CE4-4118-85B2-746A42060ED3Q33906451-C62AEB33-5936-4775-9217-3EE28A61B526Q33950874-C53BDB51-92EB-4798-828A-1DF36FBC7D72Q34200271-5DE8C24B-3BF9-4677-BF63-B6F0EF3922E1Q34596303-321502A7-1140-4FD5-B6B8-349E36806EA6Q34596435-1C81971D-3E05-43E0-8470-343DFD75BA1DQ35846113-A8470001-AE14-475B-AEF6-BCC9835DF513Q36216479-F75E2CB7-26C3-4C98-81FC-A4549BDAF1BEQ36452357-86475A69-7366-4DE2-9656-F45CE2C4CB69Q36568925-3FF29F37-961A-426E-AA11-99B2A63B86F8Q36571794-EEA1F914-BD45-4482-AA21-627D8CAD3ABBQ36806621-788A35CC-2521-49D7-92F9-B5A34427DC60Q37231685-12DDDFFF-40B3-4071-978C-CAB31A67FBC8Q37358644-4B60F183-8232-4FA4-A1A6-49A6EA185359Q38215682-54A68AC9-0A1F-4CFF-BE05-9CDC24821769Q38222870-BF77D9FC-D07F-42B8-9EF2-D6B0199A2A1EQ38240055-A883D05F-AD6D-45A8-AF2D-399837D35BCFQ38469763-455933A7-38C6-41CF-BA29-F44038631B9CQ38569678-9826198A-F660-4875-856F-E72424DA66D7Q38594191-00E61E38-A496-4B47-96D8-DF1EE36330C3Q38696468-988D3E31-B9B8-464E-A200-BC6BA4FAB122Q38709104-B7BC36E4-1D31-4719-BB1D-0B3E3B6D6D3DQ38714060-C80A30EF-1731-45B1-A4C2-FDF91BD8705AQ38821699-5AB01F7E-0BF4-4666-8E17-C43E7A9B9656Q38988798-A0ECDBE7-B974-487E-92EE-A69B60B5CFABQ40327439-52CC10EF-794B-467B-9287-4BF44368A11CQ47955297-80DA0605-FDF7-42AD-94DD-B0D0124C70E1
P2860
External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
External Evaluation of Populat ...... o different clinical settings.
@ast
External Evaluation of Populat ...... o different clinical settings.
@en
type
label
External Evaluation of Populat ...... o different clinical settings.
@ast
External Evaluation of Populat ...... o different clinical settings.
@en
prefLabel
External Evaluation of Populat ...... o different clinical settings.
@ast
External Evaluation of Populat ...... o different clinical settings.
@en
P2093
P2860
P50
P1476
External Evaluation of Populat ...... to different clinical settings
@en
P2093
Alison Thomson
Daolun Zhang
Edmund V Capparelli
Florentia Kaguelidou
John N van den Anker
José-Esteban Peris
May Fakhoury
Toshimi Kimura
Valérie Biran
P2860
P304
P356
10.1111/J.1365-2125.2012.04406.X
P407
P577
2013-04-01T00:00:00Z